Literature DB >> 10725614

Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers.

R Schlösser1, H Wetzel, H Dörr, W Rossbach, C Hiemke, O Benkert.   

Abstract

To evaluate the subchronic effects of paroxetine, a selective serotonin reuptake inhibitor, on nocturnal endocrinological profiles, eight healthy male volunteers with no personal or family history of a psychiatric or neurological disease were administered paroxetine (30 mg/day) or placebo in a double-blind cross-over design. Drugs were given as a single dose at 10:00 h for a period of 4 weeks each. Between days 21 and 28 of each treatment period, sleep EEG was registered for four consecutive nights from 23:00 to 07:00 h. During the last night, hormonal profiles for prolactin, growth hormone (GH), cortisol, corticotropin (ACTH), luteinizing hormone (LH), testosterone and melatonin were determined, and area-under-the-curve values were calculated. None of the endocrinological parameters revealed any statistically significant changes. A trend could be found for an increased cortisol production under paroxetine (P = 0.069). ACTH, LH, and melatonin showed slight and non-significant decreases. Prolactin release was only marginally elevated (+7%). The mean sleep onset GH release (as measured for a time period of 180 min after sleep onset) was decreased by about 30% under paroxetine. However, statistical significance could not be reached. For hGH, there was a delayed mean GH-peak under paroxetine. Nocturnal testosterone secretion remained almost unaltered. The lack of significant endocrinological alterations might be partially explained by both adaptational phenomena under subchronic treatment conditions and the extended time span between the single morning dose and the registration period, respectively.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725614     DOI: 10.1016/s0306-4530(99)00065-7

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  8 in total

1.  Changes in sleep electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers.

Authors:  Heike E Kuenzel; Axel Steiger; Katja Held; Irina A Antonijevic; Ralf-Michael Frieboes; Harald Murck
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

Review 2.  Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management.

Authors:  Flora Coker; David Taylor
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

Review 3.  Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects.

Authors:  G J H Dumont; S J de Visser; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

Review 4.  Paroxetine: a review.

Authors:  M Bourin; P Chue; Y Guillon
Journal:  CNS Drug Rev       Date:  2001

Review 5.  Paroxetine: an update of its use in psychiatric disorders in adults.

Authors:  Antona J Wagstaff; Susan M Cheer; Anna J Matheson; Douglas Ormrod; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers.

Authors:  Carmine M Pariante; Andrew S Papadopoulos; Lucia Poon; Anthony J Cleare; Stuart A Checkley; Judie English; Robert W Kerwin; Stafford Lightman
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

7.  The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks.

Authors:  A Rodenbeck; S Cohrs; W Jordan; G Huether; E Rüther; G Hajak
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

8.  Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotonin-reuptake inhibitors: a cross-sectional pilot study.

Authors:  Sollip Kim; Young-Min Park
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.